Where does CellCentric's cap table come from?

Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across CellCentric's 2 recorded funding rounds.

Premier Alternatives

CellCentric

Biotechnology · Cambridge, United Kingdom · Founded 2003 · Privately Held (backing)

Operator of a clinical-stage cancer therapy biotechnology company intended to focus on novel drug development for specific cancers. CellCentric is based in Cambridge, United Kingdom and was founded in 2003. It is valued at about $382 million as of Oct 2026, set by institutional fund marks. It has raised $281 million across 2 recorded rounds; the latest was an $116 million Series C in Apr 2025.

PMV mark · valuation

$382.5M

Oct 2026

Priced at

its later-stage round

Apr 2025

Total raised

$280.5M

Last round

Later Stage VC (Series C)

Apr 2025

Cap table — not yet on record

CellCentric's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.

Pro members can request priority coverage with a 48-hour turnaround.

Pro

The prices on CellCentric

·7 fund marks: filer, period, implied $/share

Pro · $99 a month

List $299 · founding price, locked for as long as you stay

Membership and data by Private Market View

Or create a free account

Frequently asked about CellCentric

Where does CellCentric's cap table come from?: Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across CellCentric's 2 recorded funding rounds.